Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2020

01-06-2020 | Computed Tomography | Case report

A rare case of sever primary hypoparathyroidism presented with amnesia and basal ganglia calcification

Authors: Toraj Valeh, Hanieh-Sadat Ejtahed, Shirin Hasani-Ranjbar

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2020

Login to get access

Abstract

Objectives

The aim of this study was to describe clinical findings in a 45-year-old man with history of two sided cataract surgery, convulsions and progressive memory impairment.

Methods

The patient presented to the neurology department because of having progressive memory impairment over the past two years. After taking necessary examinations the patient was referred to the endocrine center because of hypocalcemia in laboratory tests. Brain CT scan and MRI was also done.

Results

Brain CT scan of patient showed extensive and symmetric calcification of basal ganglia, thalami and cerebellum. On Brain MRI, abnormal signal foci in the both sided paraventricular regions, basal ganglia and cerebellar hemisphere were depicted. Laboratory investigations were notable for low serum calcium (5.4 mg/dl, reference range: 8.2–11.2), high serum phosphorus (7.6 mg/dl, reference range: 2.7–4.5), vitamin D deficiency (25-OH D3: 14.5 ng/ml) and low parathyroid hormone (IPTH: 3.7 pg/mL, reference range: 10–62).

Conclusions

This patient presented with amnesia which is a rare presentation of hypoparathyroidism.
Literature
1.
go back to reference Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5:S23–30.CrossRef Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5:S23–30.CrossRef
2.
go back to reference De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: from diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):435–42.CrossRef De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: from diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes. 2012;19(6):435–42.CrossRef
3.
go back to reference Rosa RG, Barros AJ, de Lima A, Lorenzi W, Da Rosa R, Zambonato K, et al. Mood disorder as a manifestation of primary hypoparathyroidism: a case report. J Med Case Rep. 2014;8:326.CrossRef Rosa RG, Barros AJ, de Lima A, Lorenzi W, Da Rosa R, Zambonato K, et al. Mood disorder as a manifestation of primary hypoparathyroidism: a case report. J Med Case Rep. 2014;8:326.CrossRef
4.
go back to reference Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273–83.CrossRef Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273–83.CrossRef
5.
go back to reference Ooi HW, Er C, Hussain I, Kuthiah N, Meyyur AV. Bilateral basal ganglia calcification: Fahr's disease. Cureus. 2019;11(6):e4797.PubMedPubMedCentral Ooi HW, Er C, Hussain I, Kuthiah N, Meyyur AV. Bilateral basal ganglia calcification: Fahr's disease. Cureus. 2019;11(6):e4797.PubMedPubMedCentral
6.
go back to reference Lee YJ, Park S, Kim YW, Park KM, Kim IH, Park JH, et al. A case of seizure revealing Fahr's syndrome with primary Hypoparathyroidism. Am J Case Rep. 2018;19:1430–3.CrossRef Lee YJ, Park S, Kim YW, Park KM, Kim IH, Park JH, et al. A case of seizure revealing Fahr's syndrome with primary Hypoparathyroidism. Am J Case Rep. 2018;19:1430–3.CrossRef
7.
go back to reference Marques Mendes E, Meireles-Brandão L, Meira C, Morais N, Ribeiro C, Guerra D. Primary hypoparathyroidism presenting as basal ganglia calcification secondary to extreme hypocalcemia. Clin Pract. 2018;8(1):1007. Marques Mendes E, Meireles-Brandão L, Meira C, Morais N, Ribeiro C, Guerra D. Primary hypoparathyroidism presenting as basal ganglia calcification secondary to extreme hypocalcemia. Clin Pract. 2018;8(1):1007.
8.
go back to reference Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic Hypoparathyroidism. Clin Endocrinol. 2012;77(2):200–6.CrossRef Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic Hypoparathyroidism. Clin Endocrinol. 2012;77(2):200–6.CrossRef
9.
go back to reference Aggarwal S, Kailash S, Sagar R. Neuro-psychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168:895–903.CrossRef Aggarwal S, Kailash S, Sagar R. Neuro-psychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168:895–903.CrossRef
Metadata
Title
A rare case of sever primary hypoparathyroidism presented with amnesia and basal ganglia calcification
Authors
Toraj Valeh
Hanieh-Sadat Ejtahed
Shirin Hasani-Ranjbar
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00463-6

Other articles of this Issue 1/2020

Journal of Diabetes & Metabolic Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine